https://www.aidsmap.com/news/oct-2015/no-transmission-integrase-inhibitor-resistant-hiv-seen-california-patients
No transmission of integrase inhibitor-resistant HIV seen in California patients | aidsmap
Not one case of transmission of HIV that is resistant to any of the integrase inhibitor (INI) drugs has been seen in newly-diagnosed patients in a database of...
integrase inhibitor
https://www.aidsmap.com/news/feb-2017/integrase-inhibitor-bictegravir-matches-dolutegravir-first-line-hiv-treatment
Integrase inhibitor bictegravir matches dolutegravir for first-line HIV treatment | aidsmap
Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivicay) in a...
integrase inhibitorfirst linehiv treatmentbictegravirmatches
https://www.rti.org/publication/long-acting-integrase-inhibitor-gsk744-protects-macaques-repeated-intravaginal-shiv-challenge
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV...
Daily preexposure prophylaxis (PrEP) with Truvada is a proven HIV prevention strategy; however, its effectiveness is limited by low adherence. Antiretroviral...
integrase inhibitor
https://www.aidsmap.com/news/jul-2011/new-integrase-inhibitor-dolutegravir-looks-potent-and-well-tolerated
New integrase inhibitor dolutegravir looks potent and well-tolerated | aidsmap
The next-generation HIV integrase inhibitor dolutegravir (S/GSK1349572) suppressed HIV viral load as well as efavirenz (Sustiva, Stocrin) but caused fewer...
integrase inhibitornewdolutegravirlookspotent
https://www.aidsmap.com/news/jul-2016/new-integrase-inhibitor-bictegravir-looks-promising-early-studies
New integrase inhibitor bictegravir looks promising in early studies | aidsmap
Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favourable pharmacokinetics, good tolerability, an improved resistance...
integrase inhibitornewbictegravirlookspromising